WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage
Abstract
:1. Introduction
2. Results
2.1. AZD1775 Induces Apoptosis and Enhances Anti-Apoptotic Dependency in DLBCL
2.2. DNA Damage and Premature Mitotic Entry Induced by AZD1775 Enhance Anti-Apoptotic Dependency
2.3. AZD1775 Increases Sensitivity to BCL-2 and MCL-1 Inhibitors in DLBCL
2.4. AZD1775 Alters the Anti-Apoptotic Dependency of Patient-Derived DLBCL Cells
3. Discussion
4. Materials and Methods
4.1. Cell Lines and Culture Conditions
4.2. Patient Material and METC Statement
4.3. BH3 Profiling—Plate-Based Assay
4.4. BH3 Profiling—Flow Cytometry-Based Assay
4.5. Flow Cytometry-Based Apoptosis Assay
4.6. Flow Cytometry—Cell Cycle, γH2AX, and pH3 with DNA Content
4.7. Flow Cytometry-Based Viability Assay
4.8. Statistical Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Bakhoum, S.F.; Danilova, O.V.; Kaur, P.; Levy, N.B.; Compton, D.A. Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma. Clin. Cancer Res. 2011, 17, 7704–7711. [Google Scholar] [CrossRef] [PubMed]
- Derenzini, E.; Agostinelli, C.; Imbrogno, E.; Iacobucci, I.; Casadei, B.; Brighenti, E.; Righi, S.; Fuligni, F.; Di Rora, A.C.L.; Ferrari, A.; et al. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma. Oncotarget 2015, 6, 6553–6569. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ranuncolo, S.M.; Polo, J.M.; Dierov, J.; Singer, M.; Kuo, T.; Greally, J.; Green, R.; Carroll, M.; Melnick, A. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 2007, 8, 705–714. [Google Scholar] [CrossRef] [PubMed]
- de Jong, M.R.W.; Visser, L.; Huls, G.; Diepstra, A.; van Vugt, M.; Ammatuna, E.; van Rijn, R.S.; Vellenga, E.; van den Berg, A.; Fehrmann, R.S.N.; et al. Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach. PLoS ONE 2018, 13, e0193098. [Google Scholar] [CrossRef]
- Berry, L.D. Gould, K.L. Regulation of Cdc2 activity by phosphorylation at T14/Y15. Prog. Cell Cycle Res. 1996, 2, 99–105. [Google Scholar]
- Zuazua-Villar, P.; Ganesh, A.; Phear, G.; Gagou, M.E.; Meuth, M. Extensive RPA2 hyperphosphorylation promotes apoptosis in response to DNA replication stress in CHK1 inhibited cells. Nucleic Acids Res. 2015, 43, 9776–9787. [Google Scholar] [CrossRef]
- Haferkamp, B.; Zhang, H.; Lin, Y.; Yeap, X.; Bunce, A.; Sharpe, J.; Xiang, J. BaxDelta2 is a novel bax isoform unique to microsatellite unstable tumors. J. Biol. Chem. 2012, 287, 34722–34729. [Google Scholar] [CrossRef]
- Mattoo, A.R.; Pandita, R.K.; Chakraborty, S.; Charaka, V.; Mujoo, K.; Hunt, C.R.; Pandita, T.K. MCL-1 Depletion Impairs DNA Double-Strand Break Repair and Reinitiation of Stalled DNA Replication Forks. Mol. Cell Biol. 2017, 37. [Google Scholar] [CrossRef]
- Megyesi, J.; Tarcsafalvi, A.; Seng, N.; Hodeify, R.; Price, P.M. Cdk2 phosphorylation of Bcl-xL after stress converts it to a pro-apoptotic protein mimicking Bax/Bak. Cell Death Discov. 2016, 2, 15066. [Google Scholar] [CrossRef] [Green Version]
- Terrano, D.T.; Upreti, M.; Chambers, T.C. Cyclin-dependent kinase 1-mediated Bcl-xL/Bcl-2 phosphorylation acts as a functional link coupling mitotic arrest and apoptosis. Mol. Cell Biol. 2010, 30, 640–656. [Google Scholar] [CrossRef]
- Zhang, M.; Dominguez, D.; Chen, S.; Fan, J.; Qin, L.; Long, A.; Li, X.; Zhang, Y.; Shi, H.; Zhang, B. WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol. Lett. 2017, 14, 3580–3586. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ghelli Luserna Di Rora, A.; Beeharry, N.; Imbrogno, E.; Ferrari, A.; Robustelli, V.; Righi, S.; et al. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia. J. Hematol. Oncol. 2018, 11, 99. [Google Scholar] [CrossRef] [PubMed]
- Zhou, L.; Zhang, Y.; Chen, S.; Kmieciak, M.; Leng, Y.; Lin, H.; Rizzo, K.A.; Dumur, C.I.; Ferreira-Gonzalez, A.; Dai, Y.; et al. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia 2015, 29, 807–818. [Google Scholar] [CrossRef] [PubMed]
- Klanova, M.; Andera, L.; Brazina, J.; Svadlenka, J.; Benesova, S.; Soukup, J.; Prukova, D.; Vejmelkova, D.; Jaksa, R.; Helman, K.; et al. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. Clin. Cancer Res. 2016, 22, 1138–1149. [Google Scholar] [CrossRef]
- Iqbal, J.; Meyer, P.N.; Smith, L.M.; Johnson, N.A.; Vose, J.M.; Greiner, T.C.; Connors, J.M.; Staudt, L.M.; Rimsza, L.; Jaffe, E.; et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin. Cancer Res. 2011, 17, 7785–7795. [Google Scholar] [CrossRef]
- Potter, D.S.; Letai, A. To Prime, or Not to Prime: That Is the Question. Cold Spring Harb. Symp. Quant. Biol. 2016, 81, 131–140. [Google Scholar] [CrossRef]
- Fraser, C.; Ryan, J.; Sarosiek, K. BH3 Profiling: A Functional Assay to Measure Apoptotic Priming and Dependencies. Methods Mol. Biol. 2019, 1877, 61–76. [Google Scholar]
- Montero, J.; Sarosiek, K.A.; DeAngelo, J.D.; Maertens, O.; Ryan, J.; Ercan, D.; Piao, H.; Horowitz, N.S.; Berkowitz, R.S.; Matulonis, U.; et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015, 160, 977–989. [Google Scholar] [CrossRef]
- Ryan, J.; Letai, A. BH3 profiling in whole cells by fluorimeter or FACS. Methods 2013, 61, 156–164. [Google Scholar] [CrossRef] [Green Version]
- Deng, J.; Carlson, N.; Takeyama, K.; Dal Cin, P.; Shipp, M.; Letai, A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 2007, 12, 171–185. [Google Scholar] [CrossRef]
- Kim, H.Y.; Cho, Y.; Kang, H.; Yim, Y.S.; Kim, S.J.; Song, J.; Chun, K.H. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer. Oncotarget 2016, 7, 49902–49916. [Google Scholar] [PubMed]
- Aarts, M.; Sharpe, R.; Garcia-Murillas, I.; Gevensleben, H.; Hurd, M.S.; Shumway, S.D.; Toniatti, C.; Ashworth, A.; Turner, N.C. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. Cancer Discov. 2012, 2, 524–539. [Google Scholar] [CrossRef] [PubMed]
- Guertin, A.D.; Li, J.; Liu, Y.; Hurd, M.S.; Schuller, A.G.; Long, B.; Hirsch, H.A.; Feldman, I.; Benita, Y.; Toniatti, C.; et al. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy. Mol. Cancer Ther. 2013, 12, 1442–1452. [Google Scholar] [CrossRef] [PubMed]
- Beck, H.; Nahse-Kumpf, V.; Larsen, M.S.; O’Hanlon, K.A.; Patzke, S.; Holmberg, C.; Mejlvang, J.; Groth, A.; Nielsen, O.; Syljuåsen, R.G.; et al. Cyclin-dependent kinase suppression by WEE1 kinase protects the genome through control of replication initiation and nucleotide consumption. Mol. Cell Biol. 2012, 32, 4226–4236. [Google Scholar] [CrossRef]
- Beck, H.; Nahse, V.; Larsen, M.S.; Groth, P.; Clancy, T.; Lees, M.; Jørgensen, M.; Helleday, T.; Syljuåsen, R.G.; Sørensen, C.S. Regulators of cyclin-dependent kinases are crucial for maintaining genome integrity in S phase. J. Cell Biol. 2010, 188, 629–638. [Google Scholar] [CrossRef]
- Dai, J.; Luftig, M.A. Intracellular BH3 Profiling Reveals Shifts in Antiapoptotic Dependency in Human B Cell Maturation and Mitogen-Stimulated Proliferation. J. Immunol. 2018, 200, 1727–1736. [Google Scholar] [CrossRef]
- Schuetz, J.M.; Johnson, N.A.; Morin, R.D.; Scott, D.W.; Tan, K.; Ben-Nierah, S.; Boyle, M.; Slack, G.W.; Marra, M.A.; Connors, J.M.; et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012, 26, 1383–1390. [Google Scholar] [CrossRef]
- Adams, C.M.; Kim, A.S.; Mitra, R.; Choi, J.K.; Gong, J.Z.; Eischen, C.M. BCL-W has a fundamental role in B cell survival and lymphomagenesis. J. Clin. Investig. 2017, 127, 635–650. [Google Scholar] [CrossRef] [Green Version]
- Wilson, W.H.; O’Connor, O.A.; Czuczman, M.S.; LaCasce, A.S.; Gerecitano, J.F.; Leonard, J.P.; Tulpule, A.; Dunleavy, K.; Xiong, H.; Chiu, Y.L.; et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010, 11, 1149–1159. [Google Scholar] [CrossRef]
- Qi, B.; Hardwick, J.M. A Bcl-xL timer sets platelet life span. Cell 2007, 128, 1035–1036. [Google Scholar] [CrossRef] [PubMed]
- Ford, J.B.; Baturin, D.; Burleson, T.M.; Van Linden, A.A.; Kim, Y.M.; Porter, C.C. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget 2015, 6, 28001–28010. [Google Scholar] [CrossRef] [PubMed]
- Kanfer, G.; Kornmann, B. Dynamics of the mitochondrial network during mitosis. Biochem. Soc. Trans. 2016, 44, 510–516. [Google Scholar] [CrossRef] [PubMed]
- Taguchi, N.; Ishihara, N.; Jofuku, A.; Oka, T.; Mihara, K. Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J. Biol. Chem. 2007, 282, 11521–11529. [Google Scholar] [CrossRef] [PubMed]
- Qian, W.; Choi, S.; Gibson, G.A.; Watkins, S.C.; Bakkenist, C.J.; Van Houten, B. Mitochondrial hyperfusion induced by loss of the fission protein Drp1 causes ATM-dependent G2/M arrest and aneuploidy through DNA replication stress. J. Cell Sci. 2012, 125, 5745–5757. [Google Scholar] [CrossRef] [Green Version]
- Kamer, I.; Sarig, R.; Zaltsman, Y.; Niv, H.; Oberkovitz, G.; Regev, L.; et al. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 2005, 122, 593–603. [Google Scholar] [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
de Jong, M.R.W.; Langendonk, M.; Reitsma, B.; Herbers, P.; Nijland, M.; Huls, G.; van den Berg, A.; Ammatuna, E.; Visser, L.; van Meerten, T. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage. Cancers 2019, 11, 1743. https://doi.org/10.3390/cancers11111743
de Jong MRW, Langendonk M, Reitsma B, Herbers P, Nijland M, Huls G, van den Berg A, Ammatuna E, Visser L, van Meerten T. WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage. Cancers. 2019; 11(11):1743. https://doi.org/10.3390/cancers11111743
Chicago/Turabian Stylede Jong, Mathilde Rikje Willemijn, Myra Langendonk, Bart Reitsma, Pien Herbers, Marcel Nijland, Gerwin Huls, Anke van den Berg, Emanuele Ammatuna, Lydia Visser, and Tom van Meerten. 2019. "WEE1 Inhibition Enhances Anti-Apoptotic Dependency as a Result of Premature Mitotic Entry and DNA Damage" Cancers 11, no. 11: 1743. https://doi.org/10.3390/cancers11111743